Alzheimer’s Disease
- Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup
- Alzheimer’s Disease Facts and Figures 2024
- Focusing on earlier diagnosis of Alzheimer’s disease
- For Patients: Treatments for Alzheimer’s
- Alzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures
- Alzheimer’s disease drug development pipeline
- Treatment with GLP-1 RAs and incidence of dementia
- Donanemab in Early Symptomatic Alzheimer Disease
- Alzforum: news and information dedicated to Alzheimer’s disease
Amyotrophic Lateral Sclerosis
Migraine
- Frequently Asked Questions About Migraine Symptoms
- Atogepant for the Preventive Treatment of Migraine
Multiple Sclerosis (MS)
- Clinician Pocket Guide: What to Screen For and What to Follow When Using Disease-Modifying Therapies (DMTs)
- MS, COVID-19 and vaccines – updated global advice
- Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
- Aging and efficacy of disease-modifyingtherapies in multiple sclerosis: a meta-analysis of clinical trials
- Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years
- BEACON: BEtaferon prospective study on Adherence, COping and Nurse support): Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b
- Guidelines of the Consortium of MS Centers MRI Protocol for the Diagnosis and Follow-up of MS
- Adherence — Patient Information
- Resources for You and Your Practice
- Mobile Applications for People with Multiple Sclerosis (MS)
- Family Planning and Pregnancy With Multiple Sclerosis
- Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis
- Disease-modifying Therapies for MS
Myasthenia Gravis
- International Consensus Guidance for Management of Myasthenia Gravis
- International Consensus Guidance for Management of Myasthenia Gravis – 2020 Update
- Myasthenia Gravis Foundation of America
- NIH – Myasthenia Gravis
- Treatment options for myasthenia gravis
- New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making
- Myasthenia gravis: the future is here
- New and emerging treatments for myasthenia gravis
- Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study
- The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis
- Measuring Clinical Treatment Response in Myasthenia Gravis
Parkinson’s Disease
Stroke
- Impact of Echocardiographic Parameters on Recurrent Stroke in the Randomized REDUCE PFO Cryptogenic Stroke Trial
- Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke
- Etiologic Workup in Cases of Cryptogenic Stroke: A Systematic Review of International Clinical Practice Guidelines
- Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke
- Signs and Symptoms of a Stroke
- Recognize Warning Signs of a Stroke (Act FAST)
- Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale-Associated Stroke
- American Academy of Neurology practice advisory update: Patent foramen ovale and secondary stroke prevention
- REDUCE trial: Five-Year Outcomes of PFO Closure or Antiplatelet Therapy for Cryptogenic Stroke
